Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce

This article was originally published in The Tan Sheet

Executive Summary

Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
Advertisement

Related Content

Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Xenical Switch Proposal Will Face Advisory Committee Review In January
Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
Xenical Rx-To-OTC Switch Filing Slated For 2005
Blues HSA Plans To Go Nationwide As Medicare Drug Benefit Kicks In
FDA Panel Opposes Lowering BMI Criteria For Obesity Clinical Trials
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
Bayer Aims For Global Analgesic Market Dominance With Aleve, Aspirin
Bayer Aims For Global Analgesic Market Dominance With Aleve, Aspirin

Topics

Advertisement
UsernamePublicRestriction

Register

PS097102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel